Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Flagship Pioneering
AddedFeb 13, 2024
UpdatedJul 2, 2026
Flagship Pioneering

Flagship Pioneering

Operating

Flagship Pioneering, Inc., a US-based venture capital firm, invests in pharmaceutical, electronic, and medical sectors.

Location
Cambridge, MA, US
Founded
2000
Firm
Analysis
Compare
Portfolio
Employees
Website

Investments

Lila Sciences
Lila Sciences
Series A

Total Raised

$550M

Rounds

2

Series A$350MOctober 2025
Seed$200MMarch 2025
Inari Agriculture
Inari Agriculture

Total Raised

$609M

Rounds

7

Series F$103MJanuary 2024
Series E$124MOctober 2022
Syros Pharmaceuticals
Syros Pharmaceuticals
Public

Total Raised

$620.5M

Rounds

12

Post Ipo Equity$45MDecember 2023
Harbinger Health
Harbinger Health

Total Raised

$190M

Rounds

2

Series B$140MSeptember 2023
Series A$50MDecember 2021
Indigo
Indigo

Total Raised

$1.4B

Rounds

11

Series Unknown$250MSeptember 2023
Generate Biomedicines
Generate Biomedicines

Total Raised

$693M

Rounds

3

Series C$273MSeptember 2023
Series B$370MNovember 2021
Alltrna
Alltrna

Total Raised

$159M

Rounds

2

Series B$109MAugust 2023
Series Unknown$50MNovember 2021
Empress Therapeutics
Empress Therapeutics

Total Raised

$50M

Rounds

1

Series Unknown$50MJune 2023
Metaphore Biotechnologies
Metaphore Biotechnologies

Total Raised

$50M

Rounds

1

Series D$50MMay 2023
Ring Therapeutics
Ring Therapeutics

Total Raised

$253.5M

Rounds

3

Series C$86.5MMarch 2023
Ampersand Biomedicines
Ampersand Biomedicines

Total Raised

$50M

Rounds

1

Series Unknown$50MMarch 2023
Montai Health
Montai Health

Total Raised

$50M

Rounds

1

Series A$50MDecember 2022
Cellarity
Cellarity

Total Raised

$294M

Rounds

3

Series C$121MOctober 2022
Senda Biosciences
Senda Biosciences

Total Raised

$309M

Rounds

3

Series C$123MAugust 2022
Apriori Bio
Apriori Bio

Total Raised

$50M

Rounds

1

Series A$50MJuly 2022
ProFound Therapeutics
ProFound Therapeutics

Total Raised

$75M

Rounds

1

Series A$75MMay 2022
Vesalius Therapeutics
Vesalius Therapeutics

Total Raised

$75M

Rounds

1

Series A$75MMarch 2022
Cibo Technologies
Cibo Technologies

Total Raised

$67.4M

Rounds

9

Series C$30MOctober 2021
YourBio Health
YourBio Health

Total Raised

$98.2M

Rounds

18

Series Unknown$21MSeptember 2021
Laronde
Laronde

Total Raised

$490M

Rounds

2

Series B$440MAugust 2021